Anne Wojcicki: Driving Discovery and Disruption [Entire Talk]

TL;DR

23andMe began as an attempt to give consumers direct access to their genetic information and challenge a healthcare system that Anne Wojcicki believed gave individuals too little power. Her strategy combined affordable genetic testing, crowdsourced health research, patient education, and persistence through regulatory scrutiny and slow consumer adoption.

Transcript

• Edith Nourse for what happened from getting from being a biology major do we need biology managers here ok a handful of biology man I was actually I did my PhD in neuroscience so I'm a biologist as well and how did you go from that to starting 23 me can give a little bit of a snapshot of your story sure so I um I think the real like that's the ad... Read More

Key Insights

• Anne Wojcicki's career path was shaped by continued learning and serendipity rather than a fixed plan. After studying biology, she worked as a nanny, attended a job fair at her mother's urging, and unexpectedly entered Wall Street through connections created by submitting her CV.
• Healthcare investing gave Wojcicki ten years of exposure to companies, executives, academics, and emerging medical research. The work initially appealed to her because she could keep learning about molecular biology and projects such as transplanting animal organs into humans.
• Wojcicki's dissatisfaction with healthcare grew from a conflict between financial performance and patient welfare. She recalled companies celebrating stronger margins from collecting money from uninsured people, an example that made the industry's incentives feel inconsistent with her values.
• The founding idea behind 23andMe was to combine personal health information with crowdsourcing. Wojcicki believed people shared an interest in health and could collectively create an exceptionally large study without depending entirely on pharmaceutical companies or individual academic institutions.
• Consumer empowerment is central to Wojcicki's view of genetic testing. She argued that a genome is a digital representation of its owner and that individuals should be able to connect their own biological data with genetics research funded by taxpayer dollars.
• Affordable genetic technology made 23andMe feasible when it launched. Wojcicki said a whole-genome chip could produce extensive genetic data for about one thousand dollars, while Illumina's platform remained reliable and became progressively cheaper over time.
• Consumer adoption changed more slowly than the underlying technology. Wojcicki said many people did not understand why they would want genetic information because society trained them to wait for doctors or other authorities to identify what mattered for their health.
• Social and regulatory disruption requires patience, experimentation, and education. Wojcicki concluded that conventional marketing research could not reveal demand for an unfamiliar service, so 23andMe had to teach consumers, repeatedly try ideas, accept failures, and navigate controversy around direct consumer access.

Questions & Answers

Q: Why did Anne Wojcicki start 23andMe?

Anne Wojcicki started 23andMe after becoming frustrated with a healthcare system that she believed did not reflect her values and gave consumers too little power. She envisioned collecting health information at a massive scale, giving individuals access to their genetic data, and using crowdsourcing to advance research. The company was conceived as a rebellion against established healthcare structures and assumptions.

Q: How did Anne Wojcicki move from biology into healthcare investing?

Anne Wojcicki graduated as a biology major without a job plan, drove across the country, and worked as a nanny for a Stanford professor and his wife. Her mother encouraged her to attend a job fair, where she submitted her CV. That chance action led through several connections to an interview with the Wallenberg family and ultimately to a Wall Street career investing in healthcare companies.

Q: What did Anne Wojcicki learn from working on Wall Street?

During ten years of healthcare investing, Anne Wojcicki learned about companies, medical innovation, molecular biology, and research by meeting executives and academics. Her first project concerned whether animal organs could be transplanted into humans. She also learned how strongly financial incentives shaped healthcare, eventually concluding that the industry's focus on revenue and margins could conflict with the welfare of patients.

Q: How was crowdsourcing supposed to support 23andMe's mission?

Wojcicki believed people share a common interest in their health and could voluntarily bring their information together. By combining personal genetic and health information at a large scale, 23andMe could create a crowdsourced study and help advance scientific understanding. Her vision reduced dependence on pharmaceutical companies and separate academic groups while allowing individuals to participate directly and receive information about themselves.

Q: Why did Anne Wojcicki believe people should access their genetic data?

Wojcicki argued that individuals own their bodies and that a genome is simply a digital representation of the person it describes. She therefore saw direct access as a basic entitlement rather than something that should be prohibited. She also noted that taxpayer dollars support genetics research, so people should be able to connect their own genetic information with findings produced through that research.

Q: What technology made 23andMe possible to launch?

A whole-genome chip made extensive genetic information available at a price Wojcicki considered affordable enough to support a consumer company. She recalled that a chip cost about one thousand dollars at the time and generated large amounts of data. She also credited Illumina with providing a reliable platform whose costs continued to fall, while noting that 23andMe still used the same basic platform.

Q: Why was consumer adoption difficult for 23andMe?

Consumer adoption was difficult because many people did not understand why they would want their genetic information. Wojcicki believed society conditioned people to wait for doctors or other authorities to tell them what mattered. Because the service introduced an unfamiliar form of consumer control, standard marketing studies could not fully reveal demand. The company instead had to educate consumers and patiently encourage new behavior.

Q: How did regulation affect 23andMe's direct-to-consumer model?

23andMe entered a controversial area because consumers interacted directly with genetic testing. Wojcicki initially viewed the service as providing information and connecting genetic data with existing research, rather than interpreting the data for consumers. The company believed its laboratory work fit under the Clinical Laboratory Information Act pathway for laboratory-developed tests, but direct consumer involvement still attracted scrutiny and regulatory debate.

Summary

In this video, the CEO of 23andMe, Anne Wojcicki, shares her journey from being a biology major to starting 23andMe. She talks about the challenges she faced, the changes in technology, market, and regulations, and the ethical considerations of genetic testing. She also discusses the importance of data, partnerships, and the future of healthcare.

Questions & Answers

Q: How did Anne go from being a biology major to starting 23andMe?

Anne explains that she did her PhD in neuroscience and was always passionate about biology and medicine. However, after graduating college, she felt that the healthcare system was not reflective of her values. She then began investing in healthcare companies and realized the potential for consumer-driven affordable healthcare. This frustration led her to start 23andMe, with the goal of empowering individuals through their genetic information.

Q: How has the technology, market, and regulations changed over time?

Anne explains that the technology they use is still the same as when they started, thanks to Illumina's reliable platform. However, the consumer market and regulations have been slower to catch up. When 23andMe first launched, the consumer was not ready for genetic testing, and even after 11 years, the consumer understanding is still evolving. As for regulations, 23andMe faced controversy and a warning letter from the FDA, but they chose to work with the agency to gain direct-to-consumer approval for their tests.

Q: What are the ethical considerations of genetic testing?

Anne believes that individuals should have the right to access their own genetic information, as it represents their own bodies. She also acknowledges the ethical debates surrounding sharing genetic information with family members and the potential risk of unnecessary worries. 23andMe focuses on giving people the choice to learn about themselves, while also respecting their choice to keep the information private. The company also takes extensive measures to protect customer privacy and obtain proper consent for research.

Q: What do you do with all the data collected by 23andMe?

Anne emphasizes that 23andMe is a data company. They use the data collected from their customers to publish research papers, collaborate with academic and pharma groups, and develop therapeutics. By following the data rather than starting with specific hypotheses, they have discovered insights in various health conditions. They also aim to use their data to transform the drug discovery process and fund preventive studies.

Q: Are you considering exploring other areas, such as the microbiome or environmental factors?

Anne explains that they always want more data and are open to exploring other areas. However, they are cautious about areas like the microbiome, as the technology and collection methods are not as reliable as in genetics. She also expresses interest in environmental testing, as it could bring truth to hypotheses about the effects of chemicals on health.

Q: How do you balance work and family?

Anne mentions that prioritization is key. She has made choices to minimize unnecessary travel, avoid time-consuming meetings, and be disciplined about what opportunities she pursues. She emphasizes the importance of being present for her family and has set strict boundaries to maintain a balance between work and family life.

Q: Do you plan to compensate people who contributed data if drugs are developed from it?

Anne believes that the research environment needs to change in terms of how it treats participants. While she acknowledges the importance of compensating participants, she does not mention any specific plans for compensating individuals if drugs are developed from their data.

Q: How did you manage to start a capital-intensive business like 23andMe?

Anne does not directly address this question in the video.

Q: What are you most excited about in the area of healthcare and genomics?

Anne expresses excitement about the enthusiasm and innovation from Silicon Valley in the field of healthcare, especially in terms of prevention and genomics. She believes that the culture of risk and innovation in the region can drive positive change in the industry. She also discusses the potential in partnering with retail companies like Walmart to make preventive healthcare more accessible to the general public.

Takeaways

Anne Wojcicki's journey from biology major to CEO of 23andMe is one of resilience, innovation, and a commitment to empowering individuals through genetic information. Her insights into the challenges of the healthcare system, the potential of data, and the importance of partnerships and prevention are inspiring. Privacy, ethics, and balancing work and family are all key considerations for 23andMe. Overall, Anne's passion for transforming healthcare and her belief in the power of data-driven solutions are evident throughout the conversation.

Summary & Key Takeaways

• Anne Wojcicki moved from biology into healthcare investing through an unexpected job opportunity. During ten years on Wall Street, she learned continuously from companies, executives, and academics, but eventually concluded that the healthcare system prioritized financial returns in ways that conflicted with her personal values and interest in better health.

• Her frustration led to a broader idea: collect health information at a massive scale, let individuals access their own genetic data, and use crowdsourcing to support research. She saw 23andMe as a rebellious effort to shift power toward consumers and challenge assumptions about who controls personal health information.

• Affordable whole-genome chips made the company technically possible, while consumer understanding and regulation created harder challenges. Wojcicki argued that people own their bodies and should access the genome representing them. She also learned that changing social behavior requires patience, repeated experimentation, consumer education, and a willingness to face controversy.